drugset / Trial / NCT04274803

Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?

NCT04274803

Phase 4 Withdrawn Tanta University
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will address the value of adding intralipid infusion in reducing pregnancy complications related to antiphospholipid syndrome

Timeline

Start
2020-04-01
Primary completion
2021-05-31
Completion
2021-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Intralipid Other / unclassified 4 ml Intravenous
Comparator Enoxaparin sodium Other / unclassified 4000 iu
Comparator Ezacard Unknown 75 mg